Although no side effects were observed in these preclinical models, future studies should test novel selective inhibitors of Pin1 in combination with other PAH drugs and also should aim to develop lung-specific delivery methods[49] to achieve efficient efficacy at low concentrations. Here, PIN1 is linked to pulmonary arterial hypertension.